权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

ANTONA-MH: Accelerating New Therapies with Objective Neurophysiological Assessment for Mental Health

ANTONA-MH：通过针对心理健康的客观神经生理学评估加速新疗法

基本信息

批准号：
105593
负责人：
金额：
$ 81.14万
依托单位：
BRAINWAVEBANK LTD.
依托单位国家：
英国
项目类别：
Collaborative R&D
财政年份：
2019
资助国家：
英国
起止时间：
2019 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=105593
关键词：
ANTONA MH Accelerating New Therapies

项目摘要

Mental health conditions like depression and schizophrenia affect millions of citizens in the UK, and have consequences for their quality of life, as well as families and wider communities. One reason that mental health conditions are difficult to treat is that it is hard to diagnose them precisely, or to know when a possible treatment is working, as that is based mostly on what a patient tells their doctor. This means that is can take weeks or months for GPs and consultants to find the best treatment for each patient, and even then many people do not respond to any treatment without unacceptable side effects. Drug companies are developing new medicines to improve this, but they have the same difficulties in finding the right volunteers for trials, and in measuring whether their new therapies work.In this project, BrainWaveBank will develop a new device to detect mental health diseases, track how symptoms develop over time, and evaluate the efficacy of therapies in treating the disease. It is an easy-to-use wearable headset, accompanied by games that test different mental capacities like emotional processing, memory, concentration, etc. and yields brain-based biomarkers of neurophysiological mechanisms and cognitive functions. This will support a transformation in psychiatric drug development, helping to enable better, cheaper, and faster drug development, and improved tailoring of therapies to an individual to improve patient outcomes and reduce cost of care.

抑郁症和精神分裂症等精神健康状况影响着英国数百万公民，并对他们的生活质量以及家庭和更广泛的社区产生影响。心理健康状况难以治疗的一个原因是，很难准确诊断它们，或者知道可能的治疗方法何时起作用，因为这主要取决于患者告诉医生的内容。这意味着全科医生和顾问可能需要数周或数月的时间才能为每位患者找到最佳治疗方法，即使如此，许多人对任何治疗都没有反应，而不会产生不可接受的副作用。制药公司正在开发新的药物来改善这一点，但他们在寻找合适的志愿者进行试验和衡量他们的新疗法是否有效方面遇到了同样的困难。在这个项目中，BrainWaveBank将开发一种新的设备来检测心理健康疾病，跟踪症状如何随着时间的推移发展，并评估治疗疾病的疗效。这是一款易于使用的可穿戴式耳机，伴随着游戏，测试不同的心理能力，如情绪处理，记忆力，注意力等，并产生基于大脑的神经生理机制和认知功能的生物标志物。这将支持精神病药物开发的转型，有助于实现更好、更便宜、更快的药物开发，并改善针对个人的治疗，以改善患者的治疗效果并降低护理成本。